期刊文献+

比伐卢定对急诊PCI患者血浆CCL5、CCL18水平的影响

Bivalirudin Effect on Plasma CCL5, CCL18 Levels in Patients with Acute PCI
下载PDF
导出
摘要 目的观察比伐卢定对急诊PCI患者血浆CCL5、CCL18水平的影响,探讨比伐卢定在急诊PCI治疗中的作用及机制。方法选取2012年12月~2014年3月我院收治的150急诊PCI治疗的急性ST段抬高型心肌梗死患者,随机分为比伐卢定组(75例)和替罗非班加肝素组(75例)。所有患者在发病12 h内行急诊PCI术。比伐卢定组院在急诊PCI术前首先静脉给予比伐卢定负荷量(0.75 mg/kg),然后,以1.75 mg/(kg·h)持续静脉点滴在PCI过程中。替罗非班加肝素组院术前静脉内注入10μg/kg替罗非班,然后以0.075μg/(kg·min)持续静脉滴注36 h,同时静脉内注入普通肝素100 U/kg。检测两组患者术前和术后的CCL5、CCL18浓度,并进行对比分析。结果和术前比较,术后24h两组患者血清中CCL5、CCL18浓度均有不同程度的降低,差异具有统计学意义(约0.05);比伐卢定组患者术后CCL5、CCL18浓度均低于替罗非班加肝素组,差异具有统计学意义(约0.05)。术后比伐卢定组和替罗非班加肝素组穿刺部位出血并发症发生率(分别为4.0%和10.67%)差异具有统计学意义(约0.05)。结论比伐卢定可通过减低急诊PCI患者血浆CCL5、CCL18水平,改善患者预后并降低穿刺部位出血并发症。 Objective To observe the bivalirudin effect on plasma CCL5,CCL18 levels in patients with emergency percutaneous coronary intervention(PCI),and to investigate the ef ect and mechanism of bivalirudin in the emergency treatment of PCI.Methods Choose patients with acute ST March in our hospital 150 emergency treatment of PCI segment elevation myocardial infarction during the period of December 2012 to March 2014,randomly divided into bivalirudin group(75 cases)and for non Luo Banga heparin group(75 cases).Al patients in the incidence of 12 hour experted emergency PCI.Operation.bivalirudin group:First,the patients were designed to receive 0.75mg/kg of bivalirudin as loading dose before PCI,and then,at 1.75 mg/(kg o h)continuous infusion in the PCI process.For Luo non Banga heparin group:preoperative intravenous injection of 10μg/kg for Luo non class,then in 0.075μg/(kg o min)continuous infusion of 36 hours,at the same time intravenous heparin 100 U/kg.Detected the concentration of CCL5 and CCL18 of two groups of patients before and after PCI,and carried on the contrast analysis.Results Compared with preoperative,reducing 24 hours two group,the concentration of CCL18 in serum of patients with CCL5 had dif erent degree after operation,the dif erence was statistical y significant(<0.05);Bivalirudin group of patients after CCL5,CCL18 concentrations were lower than for non Luo Banga heparin group,the dif erences were statistical y significant(<0.05).Postoperative bivalirudin group and for non Luo Banga heparin group,the dif erence of the incidence of bleeding complications(respectively 4%and 10.67%)was statistical y significant(<0.05).Conclusion Bivalirudin can reduce CCL5,CCL18 level in plasma of patients with emergency PCI,thereby improve the prognosis and reduce bleeding complication.
作者 姜雯 徐会圃 JIANG Wen;XU Hui-pu(Department of Cardiology,Affiliated Hospital,Binzhou Medical College,Binzhou 256603,Shandong,China)
出处 《医学信息(医学与计算机应用)》 2014年第11期236-237,共2页 Medical Information
关键词 比伐卢定 急诊PCI CCL5 CCL18 Bivalirudin Emergency percutaneous coronary intervention CCL5 CCL18
  • 相关文献

参考文献3

二级参考文献35

  • 1王栋,郭满盈,郭葆玉.趋化因子受体5在乳腺浸润性导管癌组织的表达及意义[J].第二军医大学学报,2005,26(6):657-659. 被引量:14
  • 2李琼,吴明富,宋安萍,魏军成,徐刚,卢运萍,马丁.浸润性乳腺导管癌组织中Ezrin和钙粘素E的表达与淋巴结转移的关系[J].癌症,2006,25(3):363-366. 被引量:53
  • 3Nicolson GL. Paracrine and autocrine growth mechanism in tumor metastasis to specific sites with particular emphasis on brain and lung metastasis[J]. Cancer Metastasis Rev, 1993, 12 (3-4): 325-343.
  • 4Jean PL, Jean H, Yasushi T, et al. Disruption of the CXCR4/CXCL12 chemotactic interaction during hematopoietic stem cell mobilization induced by GCSF or cyclophosphamide[J]. Clin Invest, 2003, 111(2): 187- 196.
  • 5Youngs SJ, Ali SA, Taub DD, et al. Chemokines induce migrational responses in human breast carcinoma cell Lines[J]. Int J Cancer, 1997, 71(2):257-266.
  • 6Prest SJ, Rees RC, Murdoch C, et al. Chemokines induce the cellular migration of MCF-7 human breast carcinoma cells: Subpopulations of tumour cells display positive and negative ehemotaxis and differential in vivo growth potentials[J].Clinical & Experimental Metastasis, 1999,17(5):389-396.
  • 7Karnoub AE, Dash AB, Vo AP, et al. Mesenchymal stem cells within tumour stroma promote breast cancer metastasis[J].Nature, 2007, 449(71 62):557-563.
  • 8Robinson SC, Scott KA, Wilson JL, et al. A chemokine receptor antagonist inhibits experimental breast tumor growth[J]. Cancer Research, 2003, 63 (23): 8 360-8 365.
  • 9Hunter KW. Ezrin, a key component in tumor metastasis[J].Trends Mol Med, 2004, 10(5):201-204.
  • 10Fais S, De Milito A, Lozupone F, et al. The role of FAS to Ezrin association in FAS-mediated apoptosis [J]. Apoptosis, 2005, 10(5): 941-947.

共引文献9

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部